<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01025921</url>
  </required_header>
  <id_info>
    <org_study_id>MARKAR161109</org_study_id>
    <nct_id>NCT01025921</nct_id>
  </id_info>
  <brief_title>Tracheobronchitis Prevention Trial</brief_title>
  <acronym>TRAMA</acronym>
  <official_title>Study of Inhaled Antibiotics for Prevention of Tracheobronchitis and Ventilator Associated Pneumonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Thessaly</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Thessaly</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We aim to study whether the use of inhaled antibiotics may have an impact on the incidence of&#xD;
      tracheobronchitis and pneumonia associated with the use of mechanical ventilation. The&#xD;
      investigators hypothesize that this could be possible by decreasing the population of gram&#xD;
      negative germs that colonize the lumen of tracheal tube and upper airways.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      INTRODUCTION Gram-negative bacteria have recently become endemic in many ICUs around the&#xD;
      world. Ventilator associated pneumonia (VAP) is relatively common and its parenteral&#xD;
      treatment often leads to low and sub-therapeutic concentrations of antibiotics in the lung.&#xD;
      Ventilator associated tracheobronchitis (VAT) is characterized by fever, purulent sputum,&#xD;
      positive cultures of tracheal aspirates secretions and the absence of new pulmonary&#xD;
      infiltrates on CXR. This entity is of particular interest because it is an intermediate step&#xD;
      in the pathogenesis of VAP (between colonization and VAP itself) and prolongs mechanical&#xD;
      ventilatory support. Inhaled antibiotics achieve high (both peak and trough) concentrations&#xD;
      in respiratory secretions. Endobronchial antibiotics have been given to non-cystic fibrosis&#xD;
      patients for prevention of VAP. Colistimethate sodium (colistin) given by instillation&#xD;
      decreased the incidence of Gram-negative pneumonia and did not lead to the development of&#xD;
      colistin resistant bacteria.&#xD;
&#xD;
      AIM&#xD;
&#xD;
      The study is a prospective open label randomized study which aims to clarify the effect of&#xD;
      colistin to:&#xD;
&#xD;
        1. The incidence of VAP The incidence of VAT&#xD;
&#xD;
        2. Mechanical ventilation free days&#xD;
&#xD;
        3. Incidence of multidrug resistant bacteria in tracheal aspirates cultures&#xD;
&#xD;
      METHODS Settings: The study will be performed in the ICU of the University of Larissa (12&#xD;
      beds).&#xD;
&#xD;
      Entry criteria: All intubated and tracheostomised patients, older than 18 years old with&#xD;
      duration of intubation of 48 hours.&#xD;
&#xD;
      Exclusion criteria: 1) Purulent sputum within 48 hours from admission. 2) Pneumonia within 48&#xD;
      hours of intubation 3) New chest X ray infiltrate, 4) Advanced COPD that led to intubation 5)&#xD;
      Pregnancy 6) Allergy to colistin 7) Resistance of the bacterial strain to colistin.&#xD;
&#xD;
      Tools: Randomization of the patients into two groups: the first group will receive nebulized&#xD;
      colistin and the other no treatment. The initial dose is 1000000 units and it will be doubled&#xD;
      after measurement of the drug concentration in tracheal secretions. The drug will start on&#xD;
      admission and stop after 10 days.&#xD;
&#xD;
      All patients will be given the respiratory bundle measures (semi-recumbent position, daily&#xD;
      interruption of sedation) as part of the usual daily practice of our ICU except otherwise&#xD;
      indicated.&#xD;
&#xD;
      The severity of patients will be estimated by APACHE II score on admission and SOFA score&#xD;
      thrice weekly. CPIS score as a screening tool for pneumonia will be estimated as well thrice&#xD;
      weekly.&#xD;
&#xD;
      Tracheal aspirates cultures on admission and thrice weekly thereafter for the first two weeks&#xD;
      and twice weekly thereafter.&#xD;
&#xD;
      The patients will be followed for thirty days to measure outcome.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of tracheobronchitis and ventilator associated pneumonia</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ventilator free days and ICU length of stay</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Tracheobronchitis</condition>
  <condition>Pneumonia</condition>
  <arm_group>
    <arm_group_label>Inhaled colistin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>They will receive inhaled colistin three times daily for 10 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inhaled normal saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Inhaled normal saline three times daily for 10 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>colistin (Tadim)</intervention_name>
    <description>500.000 units of inhaled colistin three times daily for 10 days</description>
    <arm_group_label>Inhaled colistin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>inhaled normal saline</intervention_name>
    <description>inhalation of 2,5cc Normal Saline via nebulisation</description>
    <arm_group_label>Inhaled normal saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All intubated and tracheostomized patients, older than 18 years old with duration of&#xD;
             intubation of 48 hours.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Purulent sputum within 48 hours from admission&#xD;
&#xD;
          -  Pneumonia within 48 hours of intubation&#xD;
&#xD;
          -  New chest X ray infiltrate&#xD;
&#xD;
          -  Advanced COPD that led to intubation&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Allergy to colistin&#xD;
&#xD;
          -  Resistance of the bacterial strain to colistin&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Hospital of Larissa</name>
      <address>
        <city>Larissa</city>
        <zip>41110</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <study_first_submitted>December 3, 2009</study_first_submitted>
  <study_first_submitted_qc>December 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2009</study_first_posted>
  <last_update_submitted>May 31, 2013</last_update_submitted>
  <last_update_submitted_qc>May 31, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 3, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Thessaly</investigator_affiliation>
    <investigator_full_name>Efstratios Manoulakas</investigator_full_name>
    <investigator_title>Professor and ICU Director Zakynthinos Epaminondas</investigator_title>
  </responsible_party>
  <keyword>Tracheobronchitis</keyword>
  <keyword>pneumonia</keyword>
  <keyword>inhaled antibiotics</keyword>
  <keyword>colistin</keyword>
  <keyword>Ventilator associated tracheobronchitis</keyword>
  <keyword>Ventilator associated pneumonia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colistin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

